Brightcove Unveils Its New Vision for the Future of Video Engagement, Powered by Proprietary AI and Customer Insight
Brightcove, the intelligent video engagement company, has today unveiled a bold new chapter in its evolution, signaling a renewed commitment to innovation, customer-centricity and meaningful digital experiences. Backed by new owner Bending Spoons, and incorporating its powerful proprietary AI technology, Brightcove is reimagining its platform to meet the growing demands of both Media and Enterprise customers.
This marks a strategic evolution in how Brightcove approaches product development, balancing cutting-edge innovation with a relentless focus on quality of experience. The company is investing in areas that matter most to its customers, including new AI-powered features developed in-house, enhanced monetization tools, and a more intuitive user experience.
Brightcove’s new direction is the result of extensive collaboration with more than 50 customers across industries, geographies, and use cases. These conversations have shaped a product strategy that is designed to meet the evolving needs of modern video teams while delivering measurable business outcomes.
At the heart of this strategy is a dual focus: Innovation and Quality of Experience. These two tracks will be pursued in parallel to ensure Brightcove continues to deliver meaningful improvements for all customers.
Innovation efforts will:
- Introduce new features, including ultra-HD live streaming, a native recommendations engine, and a pilot for a native webinar and virtual event platform.
- Expand Brightcove’s AI-powered tools, including automated metadata generation, caption generation, translation and audio dubbing in multiple languages, intelligent video clipping and reformatting to optimize for social publishing, and smart content analysis for precise advertising targeting.
Meanwhile, the Quality of Experience track will:
- Refine the core platform through targeted initiatives, such as vertical video support, animated thumbnails, and a comprehensive UX/UI revamp to streamline workflows and enhance usability.
- Implement AI features, like predictive buffering and adaptive bitrate optimization, to help ensure smoother playback across devices and networks.
A key enabler of this transformation is Bending Spoons’ proprietary AI technology. With a proven track record that includes building fully AI-powered products like Remini, as well as integrating AI features into broader platforms such as Evernote and Meetup, Bending Spoons brings deep technical expertise and a vertically integrated stack that accelerates delivery and ensures seamless integration. These capabilities will empower Brightcove to move faster, build smarter, and deliver a more polished experience from day one.
Luca Ferrari, CEO of Bending Spoons, commented: "At Brightcove, our aim is to deliver a powerful and reliable platform that is deeply aligned with the needs of modern media and enterprise users. We're enthusiastic to bring our new product strategy to life, combining customer insight with Bending Spoons' AI expertise to build a long-term strategy hand-in-hand with our customers."
About Brightcove Inc.
Brightcove creates the world’s most reliable, scalable, and secure streaming technology solutions to build a greater connection between companies and their audiences, no matter where they are or on which devices they consume content. In more than 60 countries, Brightcove’s intelligent video platform enables businesses to sell to customers more effectively, media leaders to stream and monetize content more reliably, and every organization to communicate with team members more powerfully.
About Bending Spoons
Bending Spoons has served a billion people across the globe through its suite of digital technology businesses, including Brightcove, Evernote, komoot, Meetup, Remini, StreamYard, and WeTransfer. Its products are currently used by around 300 million people each month.
For more information, visit bendingspoons.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250710991687/en/
Contacts
Brightcove Inc. Media Contact
Rebecca O'Reilly
rebecca.o'reilly@cavendishconsulting.com
Bending Spoons Media Contact
Christy Keenan
ck@bendingspoons.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM31.8.2025 12:15:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the 12-month follow-up of the ongoing open-label extension (OLE) period of HELIOS-B were presented during an oral session at the European Society of Cardiology (ESC) Congress 2025 held in Madrid, Spain. These data reflect outcomes of treatment through up to 48 months, including the initial double-blind period of 33-36 months, and highlight the ongoing clinical benefit of vutrisiran, which causes rapid knockdown of the disease-causing transthyretin (TTR) protein, including a 37% risk reduction in the composite endpoint of all-cause mortality (ACM) or first cardiovascular (CV) event in the overall population (p<0.001) and a 42% risk reduction in th
WETEX Opens Broad Investment Horizons for International Companies31.8.2025 09:30:00 EEST | Press release
Under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy, Dubai Electricity and Water Authority (DEWA) will organise the 27th edition of the Water, Energy, Technology and Environment Exhibition (WETEX) from 30 September to 2 October 2025 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250830023664/en/ WETEX opens broad investment horizons for international companies (Photo: AETOSWire) WETEX embodies the UAE's pioneering position in clean and renewable energy and sustainability. It also supports Dubai's ambitious vision of a sustainable economy. The exhibition covers multiple areas including water, energy, smart cities, green mobility, artificial intelligence and digital transformation. “WETEX reflects the UAE's unwa
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 19:00:00 EEST | Press release
Daiichi Sankyo Europe is pleased to announce the initiation of the development of new oral triple combination tablets in Europe of bempedoic acid, ezetimibe, and different doses of a statin (atorvastatin or rosuvastatin), with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.9 It is well known that combination therapies reduce the pill burden for patients, potentially enhancing treatment adherence and facilitating treatment with a goal of improving cardiovascular outcomes.9,10 “As bempedoic acid and ezetimibe are already approved as a single-dose therapy, the development of an oral triple combination tablet with different doses of a statin, can make it easier for physicians to tailor treatment to the individual needs of each patient,” says Dr. Stefan Seyfried, Vice President and Head Medical Affairs Specialty Medicines, Daiichi Sankyo Europe. “This approach exemplifies our dedication to our motto: ‘we care for every heartbeat’.” “The management of dyslipidaemia
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 17:30:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from the comprehensive KARDIA Phase 2 program, including KARDIA-3 results presented today as a late-breaking abstract at the European Society of Cardiology (ESC) Congress in Madrid, Spain. Zilebesiran is an investigational subcutaneously administered RNAi therapeutic which, in the KARDIA Phase 2 program, has shown reductions in blood pressure by targeting liver-expressed angiotensinogen (AGT), the most upstream precursor in the Renin-Angiotensin-Aldosterone System (RAAS), which plays a key role in blood pressure regulation and impacts cardiovascular and renal health. KARDIA-3, the third Phase 2 study in the KARDIA program, evaluated the efficacy and safety of zilebesiran in patients with
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and durable responses and offer the first BCL2 inhibitor for patients with R/R MCL, if approved,” said Lai Wang, PhD, Global Head of R&D, BeOne Medicines. “These data add to the remarkable progress we’ve seen over the past five years in treating B-cel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom